This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy ...

Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these personalized treatments faster, cheaper, and available to far more patients.

Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company shared top-line results from its Phase 2 study evaluating tebapivat in patients ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone ...